These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 15952188)

  • 1. Addition of an aminopeptidase N-binding sequence to human endostatin improves inhibition of ovarian carcinoma growth.
    Yokoyama Y; Ramakrishnan S
    Cancer; 2005 Jul; 104(2):321-31. PubMed ID: 15952188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modification of cyclic NGR tumor neovasculature-homing motif sequence to human plasminogen kringle 5 improves inhibition of tumor growth.
    Jiang W; Jin G; Ma D; Wang F; Fu T; Chen X; Chen X; Jia K; Marikar FM; Hua Z
    PLoS One; 2012; 7(5):e37132. PubMed ID: 22590653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved biological activity of a mutant endostatin containing a single amino-acid substitution.
    Yokoyama Y; Ramakrishnan S
    Br J Cancer; 2004 Apr; 90(8):1627-35. PubMed ID: 15083196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of integrin binding sequence to a mutant human endostatin improves inhibition of tumor growth.
    Yokoyama Y; Ramakrishnan S
    Int J Cancer; 2004 Oct; 111(6):839-48. PubMed ID: 15300795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis.
    Pasqualini R; Koivunen E; Kain R; Lahdenranta J; Sakamoto M; Stryhn A; Ashmun RA; Shapiro LH; Arap W; Ruoslahti E
    Cancer Res; 2000 Feb; 60(3):722-7. PubMed ID: 10676659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of ovarian cancer by RGD-P125A-endostatin-Fc fusion proteins.
    Jing Y; Lu H; Wu K; Subramanian IV; Ramakrishnan S
    Int J Cancer; 2011 Aug; 129(3):751-61. PubMed ID: 21225621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth.
    Yokoyama Y; Dhanabal M; Griffioen AW; Sukhatme VP; Ramakrishnan S
    Cancer Res; 2000 Apr; 60(8):2190-6. PubMed ID: 10786683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A tumor-penetrating peptide modification enhances the antitumor activity of endostatin in vivo.
    Hai-Tao Z; Hui-Cheng L; Zheng-Wu L; Chang-Hong G
    Anticancer Drugs; 2011 Jun; 22(5):409-15. PubMed ID: 21427563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A CD13-targeting peptide integrated protein inhibits human liver cancer growth by killing cancer stem cells and suppressing angiogenesis.
    Zheng YB; Gong JH; Liu XJ; Li Y; Zhen YS
    Mol Carcinog; 2017 May; 56(5):1395-1404. PubMed ID: 27991698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cysteine cathepsins S and L modulate anti-angiogenic activities of human endostatin.
    Veillard F; Saidi A; Burden RE; Scott CJ; Gillet L; Lecaille F; Lalmanach G
    J Biol Chem; 2011 Oct; 286(43):37158-67. PubMed ID: 21896479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 68Ga-DOTA-NGR as a novel molecular probe for APN-positive tumor imaging using MicroPET.
    Zhang J; Lu X; Wan N; Hua Z; Wang Z; Huang H; Yang M; Wang F
    Nucl Med Biol; 2014 Mar; 41(3):268-75. PubMed ID: 24438818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo assessment of aminopeptidase N (APN/CD13) specificity of different
    Kis A; Dénes N; Szabó JP; Arató V; Jószai I; Enyedi KN; Lakatos S; Garai I; Mező G; Kertész I; Trencsényi G
    Int J Pharm; 2020 Nov; 589():119881. PubMed ID: 32946975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis.
    Jiang WG; Lu XA; Shang BY; Fu Y; Zhang SH; Zhou D; Li L; Li Y; Luo Y; Zhen YS
    BMC Cancer; 2013 Oct; 13():479. PubMed ID: 24128285
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Kis A; Dénes N; Szabó JP; Arató V; Beke L; Matolay O; Enyedi KN; Méhes G; Mező G; Bai P; Kertész I; Trencsényi G
    Biomed Res Int; 2021; 2021():6642973. PubMed ID: 33778075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of differentially expressed genes in a renal cell carcinoma tumor model after endostatin-treatment.
    van Wijngaarden J; de Rooij K; van Beek E; Bernsen H; Que I; van Hinsbergh VW; Löwik C
    Lab Invest; 2004 Nov; 84(11):1472-83. PubMed ID: 15273700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aminopeptidase N (CD13) targeted MR and NIRF dual-modal imaging of ovarian tumor xenograft.
    Meng Y; Zhang Z; Liu K; Ye L; Liang Y; Gu W
    Mater Sci Eng C Mater Biol Appl; 2018 Dec; 93():968-974. PubMed ID: 30274135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NGR-TNF Engineering with an N-Terminal Serine Reduces Degradation and Post-Translational Modifications and Improves Its Tumor-Targeting Activity.
    Corti A; Gasparri AM; Sacchi A; Colombo B; Monieri M; Rrapaj E; Ferreri AJM; Curnis F
    Mol Pharm; 2020 Oct; 17(10):3813-3824. PubMed ID: 32805112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant adeno-associated virus 2-mediated antiangiogenic prevention in a mouse model of intraperitoneal ovarian cancer.
    Isayeva T; Ren C; Ponnazhagan S
    Clin Cancer Res; 2005 Feb; 11(3):1342-7. PubMed ID: 15709207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A unified mechanism for aminopeptidase N-based tumor cell motility and tumor-homing therapy.
    Liu C; Yang Y; Chen L; Lin YL; Li F
    J Biol Chem; 2014 Dec; 289(50):34520-9. PubMed ID: 25359769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted antitumor prodrug therapy using CNGRC-yCD fusion protein in combination with 5-fluorocytosine.
    Li JJ; Chang SF; Liau II; Chan PC; Liu RS; Yen SH; Wang HE; Chang CA
    J Biomed Sci; 2016 Jan; 23():15. PubMed ID: 26801910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.